COVID-19 臨床試驗市場：依產品、階段 - 2024-2030 年全球預測

COVID-19臨床試驗市場規模預計2023年為59.5億美元，2024年達到67.9億美元，預計2030年將達到148.4億美元，複合年成長率為13.93%。

COVID-19 臨床試驗的全球市場

FPNV定位矩陣

FPNV定位矩陣對於評估COVID-19臨床試驗市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對 COVID-19 臨床試驗市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-COVID-19臨床試驗市場的市場規模與預測是多少？

2-在 COVID-19 臨床試驗市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-COVID-19臨床試驗市場的技術趨勢和法律規範是什麼？

4-COVID-19臨床試驗市場主要供應商的市場佔有率是多少？

5-進入COVID-19臨床試驗市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 新型冠狀病毒迅速蔓延導致多人死亡
    • 政府對 COVID-19 臨床試驗的支持和津貼
    • 加強研發 (R&D) 力度以實現有效治療方法
  • 抑制因素
    • 臨床試驗管理的複雜性和臨床實驗期間副作用的風險
  • 機會
    • 製藥公司和科技公司之間的合作
    • 進口國投資增加
  • 任務
    • 全球發展中地區的基礎設施、技能和技術支援有限
• 市場區隔分析
• 市場趨勢分析
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範

第 6 章 COVID-19 臨床試驗市場：依產品

• 療法
• 疫苗

第 7 章按階段分類的 COVID-19 臨床試驗市場

• 第一階段
• 第二階段
• 第三階段
• 第四階段

第8章美洲的COVID-19臨床試驗市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章亞太地區COVID-19臨床試驗市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章歐洲、中東和非洲的COVID-19臨床試驗市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市場佔有率分析：主要企業
• 主要企業競爭情境分析

第12章競爭產品組合

• 主要公司簡介
  • AbbVie Inc.
  • Bharat Biotech Ltd.
  • BioNTech SE
  • Clario
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ICON PLC
  • Inovio Pharmaceuticals, Inc.
  • IQVIA Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Medidata Solutions
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Novotech
  • PAREXEL International Corporation
  • Pfizer Inc.
  • PPD, Inc.
  • Quanticate
  • Takeda Pharmaceutical Company Limited
• 主要產品系列

第13章附錄

• 討論指南
• 關於許可證和定價

[193 Pages Report] The COVID-19 Clinical Trials Market size was estimated at USD 5.95 billion in 2023 and expected to reach USD 6.79 billion in 2024, at a CAGR 13.93% to reach USD 14.84 billion by 2030.

Global COVID-19 Clinical Trials Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the COVID-19 Clinical Trials Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the COVID-19 Clinical Trials Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bharat Biotech Ltd., BioNTech SE, Clario, Gilead Sciences, Inc., GlaxoSmithKline PLC, ICON PLC, Inovio Pharmaceuticals, Inc., IQVIA Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Medidata Solutions, Moderna, Inc., Novartis AG, Novavax, Inc., Novotech, PAREXEL International Corporation, Pfizer Inc., PPD, Inc., Quanticate, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the COVID-19 Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Therapeutics
  • Vaccines
• Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the COVID-19 Clinical Trials Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the COVID-19 Clinical Trials Market?

3. What are the technology trends and regulatory frameworks in the COVID-19 Clinical Trials Market?

4. What is the market share of the leading vendors in the COVID-19 Clinical Trials Market?

5. Which modes and strategic moves are suitable for entering the COVID-19 Clinical Trials Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. COVID-19 Clinical Trials Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
    • 5.1.1.2. Government Support and Grants for COVID-19 Clinical Trials
    • 5.1.1.3. Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in Clinical Trial Management and Risk of Side Effects During Trials
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative Efforts of Pharma and Technology Firms
    • 5.1.3.2. Rising Investment from Importing Countries
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. COVID-19 Clinical Trials Market, by Product

• 6.1. Introduction
• 6.2. Therapeutics
• 6.3. Vaccines

7. COVID-19 Clinical Trials Market, by Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III
• 7.5. Phase IV

8. Americas COVID-19 Clinical Trials Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific COVID-19 Clinical Trials Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa COVID-19 Clinical Trials Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

• 12.1. Key Company Profiles
  • 12.1.1. AbbVie Inc.
  • 12.1.2. Bharat Biotech Ltd.
  • 12.1.3. BioNTech SE
  • 12.1.4. Clario
  • 12.1.5. Gilead Sciences, Inc.
  • 12.1.6. GlaxoSmithKline PLC
  • 12.1.7. ICON PLC
  • 12.1.8. Inovio Pharmaceuticals, Inc.
  • 12.1.9. IQVIA Inc.
  • 12.1.10. Johnson & Johnson Services, Inc.
  • 12.1.11. Laboratory Corporation of America Holdings
  • 12.1.12. Medidata Solutions
  • 12.1.13. Moderna, Inc.
  • 12.1.14. Novartis AG
  • 12.1.15. Novavax, Inc.
  • 12.1.16. Novotech
  • 12.1.17. PAREXEL International Corporation
  • 12.1.18. Pfizer Inc.
  • 12.1.19. PPD, Inc.
  • 12.1.20. Quanticate
  • 12.1.21. Takeda Pharmaceutical Company Limited
• 12.2. Key Product Portfolio

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. COVID-19 CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. COVID-19 CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. COVID-19 CLINICAL TRIALS MARKET SIZE, 2023-2030 (USD MILLION)
• FIGURE 4. COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. COVID-19 CLINICAL TRIALS MARKET DYNAMICS
• FIGURE 7. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 10. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. COVID-19 CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
• FIGURE 20. COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

• TABLE 1. COVID-19 CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2023-2023
• TABLE 3. COVID-19 CLINICAL TRIALS MARKET SIZE, 2023-2030 (USD MILLION)
• TABLE 4. GLOBAL COVID-19 CLINICAL TRIALS MARKET SIZE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 5. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 6. COVID-19 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 7. COVID-19 CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 8. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 9. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2023-2030 (USD MILLION)
• TABLE 10. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2023-2030 (USD MILLION)
• TABLE 11. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2023-2030 (USD MILLION)
• TABLE 12. COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2023-2030 (USD MILLION)
• TABLE 13. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 14. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 15. AMERICAS COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 16. ARGENTINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 17. ARGENTINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 18. BRAZIL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 19. BRAZIL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 20. CANADA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 21. CANADA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 22. MEXICO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 23. MEXICO COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 24. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 25. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 26. UNITED STATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY STATE, 2023-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30. AUSTRALIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 31. AUSTRALIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 32. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 33. CHINA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 34. INDIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 35. INDIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 36. INDONESIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 37. INDONESIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 38. JAPAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 39. JAPAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 40. MALAYSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 41. MALAYSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 42. PHILIPPINES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 43. PHILIPPINES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 44. SINGAPORE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 45. SINGAPORE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 48. TAIWAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 49. TAIWAN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 50. THAILAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 51. THAILAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 52. VIETNAM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 53. VIETNAM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 57. DENMARK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 58. DENMARK COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 59. EGYPT COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 60. EGYPT COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 61. FINLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 62. FINLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 63. FRANCE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 64. FRANCE COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 65. GERMANY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 66. GERMANY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 67. ISRAEL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 68. ISRAEL COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 69. ITALY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 70. ITALY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 71. NETHERLANDS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 72. NETHERLANDS COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 73. NIGERIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 74. NIGERIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 75. NORWAY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 76. NORWAY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 77. POLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 78. POLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 79. QATAR COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 80. QATAR COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 81. RUSSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 82. RUSSIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 87. SPAIN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 88. SPAIN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 89. SWEDEN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 90. SWEDEN COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 91. SWITZERLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 92. SWITZERLAND COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 93. TURKEY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 94. TURKEY COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM COVID-19 CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023-2030 (USD MILLION)
• TABLE 99. COVID-19 CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
• TABLE 100. COVID-19 CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. COVID-19 CLINICAL TRIALS MARKET LICENSE & PRICING